ArticlePloS one2012
Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Temporal trends in viral setpoint and peak CD4 + cell count soon after HIV-1 seroconversion.AIDS (London, England) · 2026Observational
- HIV disease progression among heterosexually-infected individuals before the introduction of universal ART in China: A linear mixed-effects model.Global health & medicine · 2024Article
- Prevalence of and factors associated with late diagnosis of HIV in Malawi, Zambia, and Zimbabwe: Results from population-based nationally representative surveys.PLOS global public health · 2022Article
- Disease progression and mortality with untreated HIV infection: evidence synthesis of HIV seroconverter cohorts, antiretroviral treatment clinical cohorts and population-based survey data.Journal of the International AIDS Society · 2021Article
- Cohort Profile: IAVI's HIV epidemiology and early infection cohort studies in Africa to support vaccine discovery.International journal of epidemiology · 2021Article
- Article
- Joint estimation of CD4+ cell progression and survival in untreated individuals with HIV-1 infection.AIDS (London, England) · 2017Article
- A pseudo-random patient sampling method evaluated.Journal of clinical epidemiology · 2017Article
- Effectiveness of combination packages for HIV-1 prevention in sub-Saharan Africa depends on partnership network structure: a mathematical modelling study.Sexually transmitted infections · 2016Article
- Limiting Cumulative HIV Viremia Copy-Years by Early Treatment Reduces Risk of AIDS and Death.Journal of acquired immune deficiency syndromes (1999) · 2016Article
- CD4+ cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, sex and calendar time.AIDS (London, England) · 2015Article
- Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?AIDS (London, England) · 2015Article
- New indicators for delay in initiation of antiretroviral treatment: estimates for Cameroon.Bulletin of the World Health Organization · 2015Article
- Estimation and Short-Term Prediction of the Course of the HIV Epidemic Using Demographic and Health Survey Methodology-Like Data.PloS one · 2015Article
- Estimating PMTCT's Impact on Heterosexual HIV Transmission: A Mathematical Modeling Analysis.PloS one · 2015Article
- Article
- Increase in CD4 count among new enrollees in HIV care in the modern antiretroviral therapy era.Journal of acquired immune deficiency syndromes (1999) · 2014Article
- The undiagnosed HIV epidemic in France and its implications for HIV screening strategies.AIDS (London, England) · 2014Article
- Antiretroviral treatment outcomes amongst older adults in a large multicentre cohort in South Africa.PloS one · 2014Article
- Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy.PloS one · 2013Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
introductionIt is unknown whether HIV treatment guidelines, based on resource-rich country cohorts, are applicable to African populations.
methodsWe estimated CD4 cell loss in ART-naïve, AIDS-free individuals using mixed models allowing for random intercept and slope, and time from seroconversion to clinical AIDS, death and antiretroviral therapy (ART) initiation by survival methods. Using CASCADE data from 20 European and 3 sub-Saharan African (SSA) cohorts of heterosexually-infected individuals, aged ≥15 years, infected ≥2000, we compared estimates between non-African Europeans, Africans in Europe, and Africans in SSA.
resultsOf 1,959 (913 non-Africans, 302 Europeans-African origin, 744 SSA), two-thirds were female; median age at seroconversion was 31 years. Individuals in SSA progressed faster to clinical AIDS but not to death or non-TB AIDS. They also initiated ART later than Europeans and at lower CD4 cell counts. In adjusted models, Africans (especially from Europe) had lower CD4 counts at seroconversion and slower CD4 decline than non-African Europeans. Median (95% CI) CD4 count at seroconversion for a 15-29 year old woman was 607 (588-627) (non-African European), 469 (442-497) (European-African origin) and 570 (551-589) (SSA) cells/µL with respective CD4 decline during the first 4 years of 259 (228-289), 155 (110-200), and 199 (174-224) cells/µL (p<0.01). DISCUSSION: Despite differences in CD4 cell count evolution, death and non-TB AIDS rates were similar across study groups. It is therefore prudent to apply current ART guidelines from resource-rich countries to African populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.